创新药景气回升，创新药ETF国泰（517110）涨超2.4%

Group 1 - The core viewpoint of the article highlights the recovery of the innovative drug sector, with continuous capital inflow and a positive cycle driven by favorable policies, accelerated R&D, and international expansion [1] - The innovative drug ETF Guotai (517110) saw an intraday increase of over 2.4%, with a net capital inflow exceeding 200 million yuan in the past 20 days [1] - Multiple brokerages indicate that the domestic innovative drug industry is entering a favorable cycle characterized by normalized medical insurance negotiations, continuous clinical data releases, and successful License-out orders, enhanced by AI-driven R&D acceleration [1] Group 2 - The industry valuation is currently at a historical low to mid-range, with institutional allocation being relatively low, indicating ample room for future increases [1] - The innovative drug ETF Guotai (517110) tracks the CSI Hong Kong-Shenzhen-Shanghai Innovative Drug Industry Index (931409), which selects high-quality companies with strong R&D capabilities focused on biopharmaceuticals and chemical drug innovation [1] - The index includes leading innovative drug companies and high-growth targets, accurately reflecting the performance of the core medical innovation sector, with long-term growth potential and investment value [1]